Clinical status and implications of antimalarial drug resistance

Peter A. Winstanley; Steve Ward; Robert W. Snow

doi:10.1016/s1286-4579(01)01523-4

Clinical status and implications of antimalarial drug resistance

Peter A. Winstanley, Steve Ward, Robert W. Snow

Tropical Disease Biology

Research output: Contribution to journal › Review article › peer-review

95 Citations (Scopus)

Abstract

Africa carries the greatest burden of disease caused by Plasmodium falciparum, and we can expect this burden to rise in the near future, mainly because of drug resistance. Although effective drugs are available (such as artemether-lumefantrine, mefloquine, atovaquone-proguanil and halofantrine) they are uniformly too expensive for routine use. Affordable options include chloroquine plus sulfadoxine-pyrimethamine (SP), amodiaquine (alone or in combination with SP) and chlorproguanil-dapsone. Artemisinin combination therapy may offer considerable advantages over alternative therapies, but its introduction faces considerable logistic difficulty.

Original language	English
Pages (from-to)	157-164
Number of pages	8
Journal	Microbes and Infection
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/s1286-4579(01)01523-4
Publication status	Published - 1 Feb 2002

Keywords

Drug resistance
Falciparum malaria

Access to Document

10.1016/s1286-4579(01)01523-4

Cite this

@article{22fe20c38f904feaa8cbfea0b75aa2cb,

title = "Clinical status and implications of antimalarial drug resistance",

abstract = "Africa carries the greatest burden of disease caused by Plasmodium falciparum, and we can expect this burden to rise in the near future, mainly because of drug resistance. Although effective drugs are available (such as artemether-lumefantrine, mefloquine, atovaquone-proguanil and halofantrine) they are uniformly too expensive for routine use. Affordable options include chloroquine plus sulfadoxine-pyrimethamine (SP), amodiaquine (alone or in combination with SP) and chlorproguanil-dapsone. Artemisinin combination therapy may offer considerable advantages over alternative therapies, but its introduction faces considerable logistic difficulty.",

keywords = "Drug resistance, Falciparum malaria",

author = "Winstanley, \{Peter A.\} and Steve Ward and Snow, \{Robert W.\}",

year = "2002",

month = feb,

day = "1",

doi = "10.1016/s1286-4579(01)01523-4",

language = "English",

volume = "4",

pages = "157--164",

journal = "Microbes and Infection",

issn = "1286-4579",

publisher = "Elsevier Masson s.r.l.",

number = "2",

}

TY - JOUR

T1 - Clinical status and implications of antimalarial drug resistance

AU - Winstanley, Peter A.

AU - Ward, Steve

AU - Snow, Robert W.

PY - 2002/2/1

Y1 - 2002/2/1

N2 - Africa carries the greatest burden of disease caused by Plasmodium falciparum, and we can expect this burden to rise in the near future, mainly because of drug resistance. Although effective drugs are available (such as artemether-lumefantrine, mefloquine, atovaquone-proguanil and halofantrine) they are uniformly too expensive for routine use. Affordable options include chloroquine plus sulfadoxine-pyrimethamine (SP), amodiaquine (alone or in combination with SP) and chlorproguanil-dapsone. Artemisinin combination therapy may offer considerable advantages over alternative therapies, but its introduction faces considerable logistic difficulty.

AB - Africa carries the greatest burden of disease caused by Plasmodium falciparum, and we can expect this burden to rise in the near future, mainly because of drug resistance. Although effective drugs are available (such as artemether-lumefantrine, mefloquine, atovaquone-proguanil and halofantrine) they are uniformly too expensive for routine use. Affordable options include chloroquine plus sulfadoxine-pyrimethamine (SP), amodiaquine (alone or in combination with SP) and chlorproguanil-dapsone. Artemisinin combination therapy may offer considerable advantages over alternative therapies, but its introduction faces considerable logistic difficulty.

KW - Drug resistance

KW - Falciparum malaria

U2 - 10.1016/s1286-4579(01)01523-4

DO - 10.1016/s1286-4579(01)01523-4

M3 - Review article

SN - 1286-4579

VL - 4

SP - 157

EP - 164

JO - Microbes and Infection

JF - Microbes and Infection

IS - 2

ER -

Clinical status and implications of antimalarial drug resistance

Abstract

Keywords

Access to Document

Fingerprint

Cite this